Skip to main content
Equibles
KROS logo

KROS · Keros Therapeutics, Inc. · Metrics

Track KROS — free

Use KROS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KROS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.31 +0.14 (+1.25%) At close · Sep 9
Russell 2000 member Rebalance outlook locked
Market Cap
$224.44M
Shares
19.83M

KROS metrics

62 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$11.31
Market cap
$224.44M

Price action

20 metrics
Price change (1W)
+0.9%
Price change (30D)
+4.5%
Price change (3M)
+10.9%
Price change (6M)
-3.5%
Price change (YTD)
-45.1%
Price change (1Y)
-27.8%
Trailing year
Price change (5Y)
-65.2%
52-week high
$21.84
52-week low
$9.91
Change from 52-week high
-48.9%
Change from 52-week low
+12.7%
Annualized volatility
50.1%
Annualized volatility (3M)
49.2%
Beta
1.1
RSI (14D)
53.5
Price vs SMA 50
+3.3%
Price vs SMA 200
-18.0%
Avg volume (3M)
237,982
Relative volume
0.3
Average dollar volume
$2.56M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
19.83M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
15.4×
reciprocal yield 6.5%
P / book
0.9
reciprocal yield 116.9%
FCF yield
-21.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-37.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2023-08-07

Profitability

9 metrics
Gross margin
—
Operating margin
-698.0%
Trailing 12 months
Net margin
-572.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$101.47M
Net income (TTM)
−$83.16M
Trailing 12 months
Diluted EPS (TTM)
$-3.22
FCF margin
-333.6%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$15.51

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$14.54M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-51.2%
Year over year · fewer shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-31.7%
Return on assets
-28.9%
Debt / equity
—
Current ratio
22.0
EBITDA (TTM)
—
Free cash flow (TTM)
−$48.49M
Quick ratio
22.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$257.61M
Latest balance sheet
Cash & equivalents
$257.61M
Total assets
$287.60M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$47.99M
Capital expenditures (TTM)
$494,000
R&D (TTM)
$75.86M
SG&A (TTM)
—
Stock compensation (TTM)
$22.87M
R&D / revenue
521.9%
Stock compensation / revenue
157.3%

Ownership (13F)

3 metrics
13F filers
132
13F filer change QoQ
-19
Institutional ownership
93.6%

Short interest

3 metrics
Short interest
5.8%
Latest settlement · 4.7 days to cover
Days to cover
4.7d
Short-squeeze score
75 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$70,066
Insider-sentiment score
34 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1664710 CUSIP 492327101 13F (30d) 94 filings 94 filers Visit website Investor relations